bococizumab (PF-04950615)

DRUG2 trials

Sponsors

Pfizer

Conditions

Cardiovascular Disease

Phase 3

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

TerminatedNCT01975376

PfizerCardiovascular Disease

Start: 2013-10-29End: 2017-03-22Updated: 2018-07-11

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

TerminatedNCT01975389

PfizerCardiovascular Disease

Start: 2013-10-29End: 2017-04-03Updated: 2019-05-01

Related Papers

Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1

Scientific Reports2022-03-116 citations

Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy

Circulation2018-05-01258 citations

Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.

2018-04-0347 citations

Abstract 23073: Cardiovascular Efficacy of PCSK9 Inhibition Among 1,578 Patients With Familial Hypercholesterolemia: The SPIRE Clinical Trials FH Analysis

Circulation2017-11-141 citations

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

New England Journal of Medicine2017-03-17624 citations